IBDEI2L3 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41238,2)
 ;;=^5138332
 ;;^UTILITY(U,$J,358.3,41239,0)
 ;;=E11.3213^^152^2030^24
 ;;^UTILITY(U,$J,358.3,41239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41239,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
 ;;^UTILITY(U,$J,358.3,41239,1,4,0)
 ;;=4^E11.3213
 ;;^UTILITY(U,$J,358.3,41239,2)
 ;;=^5138333
 ;;^UTILITY(U,$J,358.3,41240,0)
 ;;=E11.40^^152^2030^10
 ;;^UTILITY(U,$J,358.3,41240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41240,1,3,0)
 ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,41240,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,41240,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,41241,0)
 ;;=E11.51^^152^2030^12
 ;;^UTILITY(U,$J,358.3,41241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41241,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,41241,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,41241,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,41242,0)
 ;;=E11.52^^152^2030^11
 ;;^UTILITY(U,$J,358.3,41242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41242,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,41242,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,41242,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,41243,0)
 ;;=E11.620^^152^2030^5
 ;;^UTILITY(U,$J,358.3,41243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41243,1,3,0)
 ;;=3^DM Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,41243,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,41243,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,41244,0)
 ;;=E11.36^^152^2030^4
 ;;^UTILITY(U,$J,358.3,41244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41244,1,3,0)
 ;;=3^DM Type 2 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,41244,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,41244,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,41245,0)
 ;;=I10.^^152^2031^1
 ;;^UTILITY(U,$J,358.3,41245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41245,1,3,0)
 ;;=3^Essential/Primary Hypertension
 ;;^UTILITY(U,$J,358.3,41245,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,41245,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,41246,0)
 ;;=I11.0^^152^2031^12
 ;;^UTILITY(U,$J,358.3,41246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41246,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,41246,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,41246,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,41247,0)
 ;;=I11.9^^152^2031^13
 ;;^UTILITY(U,$J,358.3,41247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41247,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,41247,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,41247,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,41248,0)
 ;;=I12.0^^152^2031^5
 ;;^UTILITY(U,$J,358.3,41248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41248,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
 ;;^UTILITY(U,$J,358.3,41248,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,41248,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,41249,0)
 ;;=I12.9^^152^2031^4
 ;;^UTILITY(U,$J,358.3,41249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41249,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
 ;;^UTILITY(U,$J,358.3,41249,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,41249,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,41250,0)
 ;;=I13.0^^152^2031^8
 ;;^UTILITY(U,$J,358.3,41250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41250,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,41250,1,4,0)
 ;;=4^I13.0
